Instem shares soar following US government contract win

Shares in Instem leapt by a third on Thursday after the software provider revealed that the National Institute of Environmental Health Sciences (NIEHS) has purchased its Provantis 9 preclinical software suite via SaaS [Software-as-a-Service] to support National Toxicology Programme (NTP) studies.

Shares in Instem leapt by a third on Thursday after the software provider revealed that the National Institute of Environmental Health Sciences (NIEHS) has purchased its Provantis 9 preclinical software suite via SaaS [Software-as-a-Service] to support National Toxicology Programme (NTP) studies.

The value of the award to Instem, funded completely by the US government, is approximately $870,000 in the first year, with potential to extend and expand the agreement up to a further nine years, giving a possible total contract value for all 10 years of between $6.2m and $7.6m.

The contract also includes the ability to expand to a larger number of additional sites on the same terms, which could result in a further material increase in revenue, Instem reported.

The NTP is an inter-agency programme designed to coordinate toxicology research and development across the United states Department of Health and Human Services.

The NTP is managed by the NIEHS and supported by the US Food and Drug Administration and the Centers for Disease Control and Prevention.

Phil Reason, Chief Executive Officer of Instem, said: "Such a significant contract with the US government, won through a competitive tendering process, is not only a fantastic endorsement of Instem's innovative software but also of our strategy to support collaborative working practices.

"Our SaaS delivery model enables the sharing of the software between dispersed communities from multiple organisations. The accessibility of Provantis data will also enable the NIEHS to meet a key goal of combining study information with a broader set of biology information to improve scientific insights.

Instem is a supplier of IT applications to the early development healthcare market.

Its share price was up 33.33% to 130p at 12:05 on Thursday.

MF

Recommended

Avoid easyJet shares – there are better airlines to invest in
Share tips

Avoid easyJet shares – there are better airlines to invest in

EasyJet used to be one of Europe’s most impressive airlines. But now it is facing challenges on all fronts and losing out to the competition. Rupert …
16 May 2022
Britain’s ten most-hated shares – w/e 13 May
Stocks and shares

Britain’s ten most-hated shares – w/e 13 May

Rupert Hargreaves looks at Britain's ten-most hated shares, and what short-sellers are looking right now.
16 May 2022
Anna Macdonald and Mikhail Zverev: Investing in innovative new frontiers
Investment strategy

Anna Macdonald and Mikhail Zverev: Investing in innovative new frontiers

Merryn talks to Anna Macdonald and Mikhail Zverev of Amati about investing in growth-focused innovation in the teeth of a tech-stock selloff, and the …
12 May 2022
BT is making progress and the dividend is back – but is it time to buy yet?
Share tips

BT is making progress and the dividend is back – but is it time to buy yet?

Investors in telecoms giant BT have seen dismal returns over the last 15 years. But there are signs that it is starting to turn things around, says Ru…
12 May 2022

Most Popular

Get set for another debt binge as real interest rates fall
UK Economy

Get set for another debt binge as real interest rates fall

Despite the fuss about rising interest rates, they’re falling in real terms. That will blow up a wild bubble, says Matthew Lynn.
15 May 2022
High inflation will fade – here’s why
Inflation

High inflation will fade – here’s why

Many people expect high inflation to persist for a long time. But that might not be true, says Max King. Inflation may fall faster than expected – and…
13 May 2022
What the Ukraine crisis might mean for ESG investing
Advertisement Feature

What the Ukraine crisis might mean for ESG investing

The Ukraine crisis has brought many of the issues around ESG investing into sharper focus. Where does the sector go from here?
3 May 2022